In conclusion, this investigation pioneers the recognition of FOXP4’s substantial upregulation in ovarian cancer and its direct correlation with adverse outcomes, underscoring the imperative for comprehensive insight into the molecular intricacies of ovarian cancer. Here, FOXP4 is linked to ovarian carcinoma.